Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 353.65M | 336.01M | 335.88M | 487.81M | 410.67M |
Gross Profit | 202.33M | 200.34M | 165.33M | 281.80M | 217.22M |
EBITDA | -65.50M | 22.91M | 15.09M | 85.23M | 41.57M |
Net Income | -103.61M | -15.11M | -30.47M | 35.26M | 7.76M |
Balance Sheet | |||||
Total Assets | 772.93M | 882.58M | 883.53M | 937.16M | 840.77M |
Cash, Cash Equivalents and Short-Term Investments | 116.51M | 166.81M | 168.61M | 197.08M | 165.61M |
Total Debt | 212.13M | 186.29M | 143.48M | 129.07M | 75.02M |
Total Liabilities | 325.34M | 308.06M | 286.07M | 279.24M | 229.54M |
Stockholders Equity | 447.59M | 574.52M | 597.46M | 657.92M | 611.23M |
Cash Flow | |||||
Free Cash Flow | -54.96M | -47.39M | -35.98M | 4.67M | -43.77M |
Operating Cash Flow | -13.75M | 21.72M | 8.33M | 42.78M | 30.09M |
Investing Cash Flow | -40.17M | -67.61M | -43.98M | -31.21M | -50.63M |
Financing Cash Flow | 15.34M | 42.63M | 18.10M | 14.31M | 29.85M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | HK$33.83B | 38.53 | 37.28% | 0.98% | 59.83% | 68.29% | |
74 Outperform | HK$522.50M | 4.06 | 24.41% | 6.98% | 22.46% | 91.73% | |
61 Neutral | HK$514.27M | 12.52 | 5.25% | 32.26% | -23.89% | ― | |
60 Neutral | HK$17.36B | 11.06 | 0.20% | 5.39% | 2.68% | -48.29% | |
60 Neutral | HK$737.16M | 11.49 | 8.96% | ― | 30.72% | -35.61% | |
54 Neutral | HK$24.09B | ― | -7.87% | 2.92% | 16.82% | -348.71% | |
48 Neutral | HK$1.10B | ― | -20.26% | ― | 5.25% | -581.58% |
Natural Beauty Bio-Technology Limited held its Annual General Meeting on May 22, 2025, where all proposed resolutions were unanimously passed. These resolutions included the approval of financial statements, re-election of directors, and granting mandates for share repurchase and issuance, indicating strong shareholder support and strategic flexibility for the company.
Natural Beauty Bio-Technology Limited announced its Annual General Meeting, scheduled for May 22, 2025, in Taipei, Taiwan. The agenda includes reviewing financial statements, re-electing directors, appointing auditors, and granting mandates for share repurchase and issuance. These resolutions aim to strengthen the company’s governance and operational flexibility, potentially impacting its market positioning and shareholder value.